Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy

Inclusion Criteria:

* Histologically confirmed ovarian epithelial, primary peritoneal, or fallopian tube cancer
* Recurrent disease after platinum-based chemotherapy

  * Must have experienced disease persistence during primary platinum-based therapy or recurrence within 12 months after completion of platinum-based chemotherapy ("platinum-refractory" or "platinum-resistant" disease)

    * A patient receiving a second course of platinum-based chemotherapy for platinum-sensitive disease who then develops persistence or recurrence within 12 months is considered eligible for this trial
* Must have measurable disease by RECIST criteria (phase II) (phase II closed as of 1/7/2011)
* Must have received ≥ 1 prior platinum-based cytotoxic chemotherapy regimen (for primary disease) containing carboplatin, cisplatin, or other organoplatinum compound

  * Initial treatment may have included any of the following:

    * High-dose therapy
    * Consolidation therapy
    * Intraperitoneal (IP) therapy
    * Extended therapy administered after surgical or nonsurgical assessment
  * One additional non-cytotoxic regimen (e.g., monoclonal antibodies, cytokines, or small-molecule inhibitors) for recurrent or persistent disease allowed
* Patients may have received hormonal therapy for management of disease (e.g., SERMs, aromatase inhibitors, progestins, and GnRH agonists)
* No loculated ascites for which IP distribution of virus is not expected to be feasible
* No known brain metastases
* GOG performance status (PS) 0-2 (Karnofsky PS 60-100%)
* Life expectancy \> 12 weeks
* Leukocytes ≥ 3,000/mcL
* Absolute neutrophil count ≥ 1,500/mcL
* Hemoglobin ≥ 10 g/dL
* Platelets ≥ 100,000/mcL
* Total bilirubin normal
* AST/ALT ≤ 2.5 times upper limit of normal
* Creatinine normal
* Ejection fraction \> 50% by echocardiogram or MUGA
* Cardiac enzymes normal
* Not pregnant or nursing
* Fertile patients must use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation
* Must be able to avoid direct contact with pregnant or nursing women, infants, or immunocompromised individuals while on study and for ≥ 3 weeks following the last dose of study agent administration
* Cardiac conduction abnormalities (e.g., bundle branch block, heart block) are allowed if their cardiac status has been stable for 6 months before study entry
* At least 4 weeks since most recent cytotoxic chemotherapy (6 weeks for nitrosoureas or mitomycin C)
* Recovered from adverse events due to agents administered more than 4 weeks earlier
* No prior radiotherapy to the abdomen or pelvis
* No other concurrent investigational agents
* No investigational or commercial agents or therapies other than those described below may be administered with the intent to treat the patient's malignancy

Exclusion Criteria:

* Patients in whom insertion of an IP catheter is not feasible due to surgical contraindications or abdominal and pelvic adhesions
* Known HIV infection or hepatitis B or C
* Clinically significant cardiac disease (New York Heart Association class III or IV cardiac disease) including any of the following:

  * Pre-existing arrhythmia
  * Uncontrolled angina pectoris
  * Myocardial infarction 1 year prior to study entry
  * Compromised left ventricular ejection fraction ≥ grade 2 by MUGA or echocardiogram
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements
* Chronic oral steroids at an equivalent dose of prednisone 5 mg daily

  * Inhaled steroids allowed
* Patients on immunosuppressive therapy
* Concurrent routine prophylactic use of growth factor (filgrastim \[G-CSF\] or sargramostim \[GM-CSF\])